Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Angina Pectoris/MI
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Angina Pectoris/MI
    TopAbstracts in Angina Pectoris/MI 08/06/2008 - (DGNews)
    MDCT as Accurate as MRI in Assessing Myocardial Infarction in ER Setting - (DGNews)
    TopAbstracts in Angina Pectoris/MI 07/23/2008 - (DGNews)
    Apolipoprotein Ratios Better Than Cholesterol Ratios for Predicting Heart Attack Risk - (DGNews)
    Updated Boxed Warning for Micro-Bubble Contrast Agents - (DGNews)

    News archive

     Recent webcasts/CME - Angina Pectoris/MI
    • Late Breaking Data From Clinical Trials on RAAS Inhibition
    • The Changing Landscape in the Management of Hypertension and Cardiovascular Risk
    • Beyond the Management of Hypertension With RAAS Inhibitors: A Guide for General Practitioners
    • Understanding Metabolic Dysfunction in HIV
    • Importance of Reducing Ischemic Time for Optimal Treatment of ST Elevation MI

      Webcasts/CME archive

       Recent cases - Angina Pectoris/MI
        The Effect of a Large Proximal Haemodialysis A-V Fistula on Weaning off Cardiopulmonary Bypass
        Diagnostic Uncertainty of Takotusbo Cardiomyopathy Presenting as Acute Myocardial Infarction in a Woman with Cardiovascular Risk Factors Hijacked at Gunpoint: A Case Report
        The Role of Intravascular Ultrasound in the Management of Spontaneous Coronary Artery Dissection
        Unusual Cause of Exercise-Induced Ventricular Fibrillation in a Well-Trained Adult Endurance Athlete: A Case Report
        Myocardial Ischemia in the Absence of Epicardial Coronary Artery Disease in Friedreich's Ataxia

        Cases archive
          




        my personal edition > angina pectoris/mi > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Eplerenone Provides Cardioprotective Benefits in Patients with Heart Failure Complicated By Myocardial Infarction: Presented at ESH

        By Jill Stein

        PARIS, FRANCE -- June 17, 2004 -- The addition of the selective aldosterone blocker eplerenone (Inspra) to routine treatment for systolic left ventricular dysfunction and heart failure post-myocardial infarction significantly reduces morbidity and mortality in high-risk patients, say researchers.

        According to data reported on June 16th at the 14th meeting of the European Society of Hypertension (ESH), the findings from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and SUrvival (EPHESUS) study also show that the approach benefits patients with hypertension and other cardiovascular diseases. The results were presented by Faiez Zannad, MD, with the department of cardiovascular diseases at Inserm-CHU in Nancy, France.

        The EPHESUS study involved 6642 patients, 3 to 14 days post acute MI, who were randomized to 4 weeks of treatment with eplerenone 25 mg/d or placebo, after which the doses of eplerenone were titrated to a target of 50 mg/d. Eplerenone or placebo was administered in addition to optimal medical therapy, which included angiotensin-converting-enzyme inhibitors and beta blockers.

        All participants in the study had an acute MI, a left ventricular ejection fraction of 40 % or less, and pulmonary rales. The mean length of follow up was 16 months.

        The study findings indicate that eplerenone plus conventional therapy was associated with a 15% relative risk reduction in total mortality (P =.008), a 17% relative risk reduction in cardiovascular mortality (P =.005), and a 13% relative risk reduction in cardiovascular mortality/cardiovascular hospitalization (P =.002) compared with patients treated with placebo on top of standard therapy.

        There were also reductions in the rate of sudden death from cardiac causes (RR 0.79, P =.03).

        After 1 week and 1 year, systolic blood pressure and diastolic blood pressure increased in both groups from baseline, although the increases were smaller in the eplerenone group. At one year, the increase was 8/4 versus 5/3 mmHg in the 2 groups, respectively (P < .01).

        In patients with a history of hypertension (60% of patients enrolled in EPHESUS), the benefit was even larger. Treatment with eplerenone resulted in a 23% reduction in total mortality (P =.001), a 16% reduction in cardiovascular mortality and hospitalization (P =.002), a 26% reduction in sudden cardiac death (P =.021) and a 14% reduction in heart failure mortality/heart failure hospitalizations (P =.06) compared with placebo.

        Eplerenone was well tolerated.

        Dr. Zannad said that it is particularly important to note that the benefits of eplerenone were "over and above" the effects of other therapies known to improve the natural history of patients with systolic left ventricular dysfunction post-MI.

        EPHESUS was conducted by more than 300 investigators in 37 countries.


        [Study title: 8A.1 EPHESUS: Evidence for the Cardioprotective Effects of Selective Aldosterone Blockade)



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send